IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
A Focus on Extended-spectrum β-lactamase-Producing Enterobacterales, AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Enterobacterales, Pseudomonas aeruginosa with Difficult-to-Treat Resistance, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia.
In the present document, guidance is provided on the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa), carbapenem-resistant Acinetobacter baumannii species (CRAB), and Stenotrophomonas maltophilia. Many of these pathogens have been designated urgent or serious threats by the CDC. Each pathogen causes a wide range of infections that are encountered in United States hospitals of all sizes, and that carry with them significant morbidity and mortality.
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).